Utilities of leucine rich alpha-2 glycoprotein as a biomarker for the progression of cerebral infarction
Project/Area Number |
17K08433
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Medical pharmacy
|
Research Institution | Fukuoka University |
Principal Investigator |
Irie Keiichi 福岡大学, 薬学部, 助教 (50509669)
|
Co-Investigator(Kenkyū-buntansha) |
三島 健一 福岡大学, 薬学部, 教授 (00320309)
仲村 佳彦 福岡大学, 医学部, 講師 (20632201)
佐野 和憲 福岡大学, 薬学部, 准教授 (50534343)
佐藤 朝光 福岡大学, 薬学部, 准教授 (90369025)
中野 貴文 福岡大学, 薬学部, 助教 (40804539)
|
Project Period (FY) |
2017-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 脳梗塞 / バイオマーカー |
Outline of Final Research Achievements |
In this study, we examined whether leucine rich α2 glycoprotein (LRG1) is useful as a marker for predicting the progression of cerebral ischemia using cerebral ischemic model mice and human clinical samples. As a result, we found that the plasma LRG1 concentration increases after cerebral ischemia. Thus, it was expected that the plasma LRG1 concentration would be a candidate for a biomarker of for the progression of cerebral infarction.
|
Academic Significance and Societal Importance of the Research Achievements |
脳梗塞の複雑な病態の重症度を反映する脳梗塞バイオマーカーの候補となる分子を探索することで、患者個別の予後に応じた治療計画を提案することが可能となる。本研究は脳梗塞発症時のLRG1の動態を解析した結果、脳梗塞病態において、血中LRG1濃度が増加することを明らかにした。よって、血中LRG1濃度の増加は脳梗塞病態のバイオマーカーの候補となることが期待され、血中LRG1濃度を測定することで、脳梗塞後の適切な治療計画を個別に立てるために役立つと考えられた。
|
Report
(4 results)
Research Products
(7 results)
-
[Journal Article] Long-Term Treatment with Thrombomodulin Improves Functional Outcomes after Cerebral Ischemia Even if Administration is Delayed.2019
Author(s)
Takafumi Nakano, Yoshihiko Nakamura, Kiyoshi Matsuyama, Keiichi Irie, Mako Yasumura, Yurie Hirata, Motoki Yamasaki, Kanae Misumi, Yuta Yamashita, Takayuki Myose, Koichi Matsuo, Kazunori Sano, Hidetoshi Kamimura, Hiroyasu Ishikura, Takashi Egawa, Kenichi Mishima
-
Journal Title
Thromb Haemost
Volume: 119
Issue: 03
Pages: 467-478
DOI
Related Report
Peer Reviewed
-
[Journal Article] Goreisan Prevents Brain Edema after Cerebral Ischemic Stroke by Inhibiting Aquaporin 4 Upregulation in Mice2018
Author(s)
Takafumi Nakano, Chisa Nishigami, Keiichi Irie, Yutaka Shigemori, Kazunori Sano, Yuta Yamashita, Takayuki Myose, Koji Tominaga, Koichi Matsuo, Yoshihiko Nakamura, Hiroyasu Ishikura, Hidetoshi Kamimura, Takashi Egawa, Kenichi Mishima
-
Journal Title
J Stroke Cerebrovasc Dis
Volume: 27
Issue: 3
Pages: 758-763
DOI
Related Report
Peer Reviewed
-
-
-
[Presentation] 脳梗塞マウスにおけるロイシンリッチα 2 グリコプロテインの動態2019
Author(s)
神崎 愛, 中野 貴文, 山崎 元貴, 岡野 志のぶ, 入江 圭一, 山下 郁太, 明瀬 孝之, 西上 知佐, 佐藤 朝光, 三島 健司, 松尾 宏一, 佐野 和憲, 三島 健一
Organizer
日本薬学会第139年会
Related Report
-
[Presentation] Effect of delayed treatment with ADAMTS13 on cerebral ischemic injury compared with tPAs2017
Author(s)
Takafumi Nakano, Keiichi Irie, Yuta Yamashita, Takayuki Myose, Kazunori Sano, Yoshihiko Nakamura, Tomomitsu Satho, Mamiko Kai, Koji Tominaga, Hidetoshi Kamimura, Kenichi Mishima, Takashi Egawa
Organizer
Neuroscience 2017
Related Report
Int'l Joint Research
-
[Presentation] Recombinant human soluble thrombomodulin ameliorates cerebral ischemic injury through a high-mobility group box 1 inhibitory mechanism without hemorrhagic complications in mice2017
Author(s)
Yoshihiko Nakamura, Takafumi Nakano, Keiichi Irie, Kazunori Sano, Junichi Tanaka, Yuta Yamashita, Tomomitsu Satho, Koichi Matsuo, Masayuki Fujioka, Hiroyasu Ishikura, Kenichi Mishima
Organizer
Neuroscience 2017
Related Report
Int'l Joint Research